{'fraction_non_alphanumeric': 0.03796203796203796, 'fraction_numerical': 0.013986013986013986, 'mean_word_length': 5.77027027027027, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effects of paraldehyde on the convulsions induced by administration of soman in rats

Summary— The ability of paraldehyde, a potent central nervous system depressant, to prevent the convulsions induced by the organophosphate soman, an irreversible inhibitor of acetylcholinesterase, was studied in rats. Paraldehyde (0.1–500 mg/kg, im) administered 10 min before soman (100 μg/kg, sc) did not protect against seizures. Co‐administered with atropine sulfate (10 mg/kg, im), paraldehyde produced a clear dose‐dependent anticonvulsant response. Although this pre‐treatment could delay the occurrence of death, it did not produce any change in the soman‐induced 24 h mortality rate. Thus, co‐administration of paraldehyde and atropine sulfate might constitute a valuable tool to be used against the convulsant consequences of soman poisoning. However, supplementary pre‐medication, in addition to paraldehyde and atropine sulfate, remains necessary to improve the antilethal capacity of the pre‐treatment.